Stem cell studies report back-pain improvements, but lack control groups
A review of uncontrolled trials found lower pain and disability scores after patients received disc injections of their own mesenchymal stem cells.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Pain and disability scores improved after treatment, but uncontrolled studies cannot show that injections caused those changes. At matching follow-up times, the proportions achieving >30% or >50% pain reduction from baseline did not differ significantly between stem cells alone and stem cells plus hyaluronic acid. That result does not establish equivalence.
The abstract lists pain-response rates without identifying their corresponding follow-up times and gives no detailed adverse-event results. Without control groups, its claims about effectiveness and safety remain difficult to assess.
What was studied
The treatment involved injecting mesenchymal stem cells taken from the patient into a spinal disc. The review tracked pain and disability scores over time, using each group's starting measurements as the reference.
What the summary cannot quantify
The abstract describes statistically significant reductions in pain and disability scores but provides no pooled score changes or confidence intervals. That limits interpretation of how large and precise the reported improvements were.
The original publication
Efficacy of intradiscal injection of autologous mesenchymal stem cells in the treatment of discogenic low back pain: A single arm meta-analysis.
Liu L, Xiong Y, Zhu X et al.
J Back Musculoskelet Rehabil · 2026
- PubMed ID
- 41800610
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.